Neuberger Berman Group LLC Amicus Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

  • $121 Billion
  • Q4 2024

A detailed history of Neuberger Berman Group LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 561,141 shares of FOLD stock, worth $5.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
561,141
Previous 761,730 26.33%
Holding current value
$5.16 Million
Previous $8.14 Million 35.03%
% of portfolio
0.0%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$9.36 - $12.01 $1.88 Million - $2.41 Million
-200,589 Reduced 26.33%
561,141 $5.29 Million
Q3 2024

Nov 14, 2024
SELL
$9.55 - $12.09 $764 - $967
-80 Reduced 0.01%
761,730 $8.14 Million
Q2 2024

Nov 14, 2024
BUY
$9.04 - $11.75 $2.65 Million - $3.44 Million
293,158 Added 62.55%
761,810 $7.56 Million
Q2 2024

Aug 13, 2024
BUY
$9.04 - $11.75 $2.65 Million - $3.44 Million
293,158 Added 62.55%
761,810 $7.56 Million
Q1 2024

Nov 14, 2024
SELL
$11.43 - $14.24 $2.85 Million - $3.55 Million
-249,062 Reduced 34.7%
468,652 $5.52 Million
Q1 2024

May 13, 2024
BUY
$11.43 - $14.24 $5.36 Million - $6.67 Million
468,652 New
468,652 $5.52 Million
Q4 2023

Nov 14, 2024
SELL
$9.97 - $14.52 $439,637 - $640,273
-44,096 Reduced 5.79%
717,714 $10.2 Million
Q4 2023

Feb 09, 2024
BUY
$9.97 - $14.52 $1.71 Million - $2.48 Million
171,029 Added 31.28%
717,714 $10.2 Million
Q3 2023

Nov 14, 2023
BUY
$11.78 - $13.86 $49,476 - $58,212
4,200 Added 0.77%
546,685 $6.65 Million
Q2 2023

Aug 11, 2023
BUY
$10.72 - $13.3 $2.33 Million - $2.89 Million
217,430 Added 66.89%
542,485 $6.81 Million
Q1 2023

May 12, 2023
BUY
$10.91 - $13.54 $161,675 - $200,649
14,819 Added 4.78%
325,055 $3.6 Million
Q4 2022

Feb 13, 2023
SELL
$9.89 - $12.7 $1.6 Million - $2.06 Million
-162,158 Reduced 34.33%
310,236 $3.79 Million
Q3 2022

Nov 15, 2022
SELL
$9.82 - $12.75 $35,440 - $46,014
-3,609 Reduced 0.76%
472,394 $4.93 Million
Q2 2022

Aug 15, 2022
BUY
$6.23 - $11.12 $199,528 - $356,140
32,027 Added 7.21%
476,003 $5.11 Million
Q1 2022

May 13, 2022
BUY
$7.89 - $12.48 $115,265 - $182,320
14,609 Added 3.4%
443,976 $4.2 Million
Q4 2021

Feb 11, 2022
BUY
$9.82 - $12.44 $4.22 Million - $5.34 Million
429,367 New
429,367 $4.87 Million
Q1 2021

May 13, 2021
SELL
$9.2 - $23.86 $1.5 Million - $3.89 Million
-163,011 Closed
0 $0
Q4 2020

Feb 10, 2021
SELL
$13.47 - $24.89 $902,341 - $1.67 Million
-66,989 Reduced 29.13%
163,011 $3.76 Million
Q2 2020

Aug 13, 2020
BUY
$8.86 - $15.69 $88,600 - $156,900
10,000 Added 4.55%
230,000 $3.47 Million
Q4 2019

Feb 12, 2020
SELL
$7.48 - $10.75 $690,404 - $992,225
-92,300 Reduced 29.55%
220,000 $2.14 Million
Q3 2019

Nov 13, 2019
SELL
$8.02 - $13.25 $160,400 - $265,000
-20,000 Reduced 6.02%
312,300 $2.51 Million
Q2 2019

Aug 13, 2019
BUY
$10.96 - $14.4 $1.34 Million - $1.76 Million
122,300 Added 58.24%
332,300 $4.15 Million
Q1 2019

May 13, 2019
BUY
$10.04 - $13.92 $240,959 - $334,080
24,000 Added 12.9%
210,000 $2.86 Million
Q4 2018

Feb 12, 2019
BUY
$8.38 - $13.44 $469,280 - $752,640
56,000 Added 43.08%
186,000 $1.78 Million
Q3 2018

Nov 13, 2018
BUY
$11.6 - $16.54 $464,000 - $661,600
40,000 Added 44.44%
130,000 $1.57 Million
Q2 2018

Aug 13, 2018
BUY
$13.13 - $17.09 $393,900 - $512,700
30,000 Added 50.0%
90,000 $1.41 Million
Q1 2018

May 08, 2018
SELL
$13.76 - $17.12 $82,560 - $102,720
-6,000 Reduced 9.09%
60,000 $902,000
Q4 2017

Feb 14, 2018
BUY
$12.51 - $16.24 $663,030 - $860,719
53,000 Added 407.69%
66,000 $950,000
Q3 2017

Nov 15, 2017
BUY
$11.74 - $15.78 $152,620 - $205,140
13,000
13,000 $196,000

Others Institutions Holding FOLD

# of Institutions
312
Shares Held
311M
Call Options Held
467K
Put Options Held
515K
View Full List

About AMICUS THERAPEUTICS, INC.

FOLD Quotes by TradingView
  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.58B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email